{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAFLD%2FNASH&page=5",
    "query": {
      "intervention": "NAFLD/NASH",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 289,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAFLD%2FNASH&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NAFLD%2FNASH&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T06:19:45.211Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06161571",
      "title": "A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NASH/MASH",
        "NAFLD/MASLD"
      ],
      "interventions": [
        {
          "name": "Efruxifermin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akero Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 700,
      "start_date": "2023-11-10",
      "completion_date": "2026-06-19",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 139,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161571"
    },
    {
      "nct_id": "NCT06477146",
      "title": "Milk Thistle Clinical Trial in Pediatric NAFLD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease (NAFLD)"
      ],
      "interventions": [
        {
          "name": "Milk thistle (MT)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lifestyle Modification",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Fibroscan",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "University Hospitals Cleveland Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "9 Years to 22 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-12-19",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06477146"
    },
    {
      "nct_id": "NCT01327443",
      "title": "Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Weight loss",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Exercise",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-10",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2016-10-05",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327443"
    },
    {
      "nct_id": "NCT05560607",
      "title": "Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease",
        "Fatty Liver, Nonalcoholic",
        "NAFLD",
        "Nonalcoholic Fatty Liver Disease",
        "Nonalcoholic Steatohepatitis",
        "NASH"
      ],
      "interventions": [
        {
          "name": "AZD7503 Intervention",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 19,
      "start_date": "2022-08-12",
      "completion_date": "2024-02-27",
      "has_results": false,
      "last_update_posted_date": "2025-07-20",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05560607"
    },
    {
      "nct_id": "NCT03617263",
      "title": "Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease in Women With PCOS"
      ],
      "interventions": [
        {
          "name": "Saroglitazar Magnesium 4 mg Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zydus Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 60,
      "start_date": "2019-02-12",
      "completion_date": "2024-10-28",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 13,
      "location_summary": "Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Panorama City",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03617263"
    },
    {
      "nct_id": "NCT03060538",
      "title": "A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "BFKB8488A",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 154,
      "start_date": "2017-03-05",
      "completion_date": "2019-12-13",
      "has_results": false,
      "last_update_posted_date": "2020-03-27",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 17,
      "location_summary": "Anniston, Alabama • Coronado, California • Stanford, California + 12 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tustin",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03060538"
    },
    {
      "nct_id": "NCT01006889",
      "title": "Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-01",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2016-09-28",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01006889"
    },
    {
      "nct_id": "NCT03205150",
      "title": "Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obese Patients With Non-alcoholic Steatohepatitis (NASH)"
      ],
      "interventions": [
        {
          "name": "LIK066",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 107,
      "start_date": "2017-10-04",
      "completion_date": "2019-11-14",
      "has_results": true,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 4,
      "location_summary": "Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Live Oak",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03205150"
    },
    {
      "nct_id": "NCT06126354",
      "title": "Dexamethasone/Pancreatic Clamp P&F",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Prediabetic State",
        "Non-Alcoholic Fatty Liver Disease",
        "Overweight and Obesity"
      ],
      "interventions": [
        {
          "name": "Insulin human",
          "type": "DRUG"
        },
        {
          "name": "Octreotide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Glucagon",
          "type": "DRUG"
        },
        {
          "name": "Human Growth Hormone",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone Oral",
          "type": "DRUG"
        },
        {
          "name": "[6,6-2H2] D-glucose",
          "type": "OTHER"
        },
        {
          "name": "20% D-glucose (aq)",
          "type": "DRUG"
        },
        {
          "name": "BOOST Plus",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Harvard Apparatus PHD ULTRA CP syringe pump",
          "type": "DEVICE"
        },
        {
          "name": "Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer",
          "type": "DEVICE"
        },
        {
          "name": "Normal saline",
          "type": "OTHER"
        },
        {
          "name": "Human albumin",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "DIETARY_SUPPLEMENT",
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-07-01",
      "completion_date": "2026-03-31",
      "has_results": false,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06126354"
    },
    {
      "nct_id": "NCT04216589",
      "title": "Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Semaglutide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2021-02-19",
      "completion_date": "2023-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-10-01",
      "last_synced_at": "2026-11-19T06:19:45.211Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Aurora, Colorado • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04216589"
    }
  ]
}